1. Home
  2. IKT

IKT

Inhibikase Therapeutics Inc.

Logo Inhibikase Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 10:32am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Founded: N/A Country:
United States
United States
Employees: 9 City: ATLANTA
Market Cap: 13.4M IPO Year: 2020
Target Price: $27.00 AVG Volume (30 days): 138.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.57 EPS Growth: N/A
52 Week Low/High: $0.79 - $4.35 Next Earning Date: 05-13-2024
Revenue: $260,501 Revenue Growth: 111.03%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: